Nanocarrier mediated co-delivery of phytochemicals and chemo-drugs: an emerging strategy to combat lung cancer in a systemic way

초록

Lung cancer is listed as one of the hotfooted malignancies on the basis of mortality and morbidity. Thus, emergence of new targeting and immunotherapies is being recognized that later invited drug resistance. Therefore, a new strategic formulation of phytochemicals as potent antitumor has been beautifully adapted. Elimination of cancer cells preferentially through cell cycle arrest and apoptosis with negligible toxic effects seems to be the major theme in cancer treatment. Recently, the application of phytochemical-derived conjugated chemotherapeutic agents is gaining preference due to their biocompatibility, low cytotoxicity, low resistance and dynamic physico-chemical properties that discriminate normal cells from treated populations. A systematic evaluation of biological interactions of functional phytocompounds with respect to their synthetic counterparts always receives priority from entry, biodistribution, cellular/molecular interactions to excretion. Nanotechnology has revolutionized cancer therapy, including lung cancer. Tissue-specific phyto-nanomedicines using liposomes, micelles and nanoparticles as precise and effective delivery vehicles are making regular breakthroughs in the field of diagnostics. This article precisely summarizes the achievements by Food and Drug Administration, USA approved therapeutic phytomolecules in conjugation with phyto-chemopreventives for clinical trials. Furthermore, it justifies, how the selection of nanocarriers and the best pair of phytomedicine/chemodrugs are important determinants of therapy benefits. In addition, a detailed coverage is given to describe the long journey of phytochemicals in synergy with chemo-preventive from agro-field to medical field and their graceful transformation on the platform of nanotechnology as an anticancer drug. However, it is equally important to address current challenges and future perspectives.

키워드